<DOC>
	<DOCNO>NCT01547143</DOCNO>
	<brief_summary>The investigator would like propose pilot study evaluate efficacy etoposide combine immunosuppressive agent adult secondary hemophagocytic lymphohistiocytosis ( HLH ) , order prove whether modification previous HLH-94 HLH-2004 protocol childhood patient improve outcome decrease toxicity . The result pilot study base more-improved phase-2 protocol .</brief_summary>
	<brief_title>Pilot Study Etoposide-based Therapy Hematopoietic Cell Transplantation Hemophagocytic Lymphohistiocytosis</brief_title>
	<detailed_description>The treatment HLH adult patient determine yet . Actually , adopt treatment protocol HLH2004 , develop pediatric HLH patient . The HLH2004 protocol , potent successful treatment HLH , show limitation treatment adult HLH . First , dose etoposide somewhat high adult patient tolerate . Second , high incidence opportunistic infection fungal , bacterial , viral threaten patient . Third , aggressive intensive approach adopt allogeneic hematopoietic cell transplantation need earlier adult patient . Based rationale , develop modify protocol base HLH2004 pit treatment adult HLH patient .</detailed_description>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients whose clinical finding satisfy 5 criterion follow 8 one 1 . Fever ≥ 38.5 ℃ ≥ 7 day 2 . Splenomegaly ≥ 3 FB leave subcostal margin 3 . Cytopenias affect ≥ 2 3 lineage PB Hb &lt; 9 g/L Platelet &lt; 100 x 109 /L ANC &lt; 1.0 x 109 /L 4 . Hypertriglyceridemia and/or hypofibrinogenemia ( fast triglyceride ≥ 265 mg/dL , fibrinogen ≤ 1.5 g/L ) 5 . Hemophagocytosis BM spleen LN 6 . Low absent NKcell activity ( accord local laboratory reference ) 7 . Serumferritin ≥ 500 mcg/L 8 . Soluble CD25 ( sIL2 receptor ) ≥ 2,400 U/ml 18 year age . All patient ( his/her family patient sign consent form his/her general condition ) give write informed consent accord guideline institution 's committee human research . HLH malignancy ( lymphoma , myeloma , leukemia , solid tumor ) HLH rheumatic disorder ( SLE , AOSD , antiphospholipid antibody syndrome ) Patients psychiatric disorder mental deficiency severe make compliance treatment unlike , make informed consent impossible Nursing woman , pregnant woman , woman childbearing potential want adequate contraception Male patient reject method avoid pregnancy via method abstinence , barrier method ( condom etc ) . Patients diagnosis prior malignancy unless diseasefree least 5 year follow therapy curative intent ( except curatively treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Secondary hemophagocytic lymphohistiocytosis adult</keyword>
</DOC>